Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases

Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases

Stereotactic ablative radiotherapy (SABR) planning for adrenal metastases aims to minimize doses to the adjacent kidney. Renal dose constraints for SABR delivery are not well defined. In 20 patients who underwent MR-guided breath-hold SABR in five daily fractions of 8–10 Gy, ipsilateral renal volume...

Full description

Bibliographic Details
Main Authors:	John R. van Sörnsen de Koste, Claire C. van Vliet, Famke L. Schneiders, Anna M.E. Bruynzeel, Berend J. Slotman, Miguel A. Palacios, Suresh Senan
Format:	Article
Language:	English
Published:	Elsevier 2021-10-01
Series:	Physics and Imaging in Radiation Oncology
Subjects:	SABR Adrenal Kidney Organ at Risk Renal dose constraints
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405631621000518

Similar Items

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
by: Julia Malone, BSC, et al.
Published: (2020-11-01)

Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy
by: Tobias Finazzi, et al.
Published: (2020-04-01)

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
by: Shankar Siva, et al.
Published: (2018-10-01)

The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer
by: Shyama U. Tetar, et al.
Published: (2020-09-01)

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
by: Faiez Al-Shafa, et al.
Published: (2019-06-01)

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
by: Nicholas Hardcastle, et al.
Published: (2019-09-01)

Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy
by: E. Leung, et al.
Published: (2020-01-01)

Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results
by: Boda-Heggemann Judit, et al.
Published: (2012-06-01)

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer
by: Dan Yang, et al.
Published: (2020-03-01)

Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study
by: Bai Y, et al.
Published: (2018-05-01)

Organizing pneumonia after stereotactic ablative radiotherapy of the lung
by: Murai Taro, et al.
Published: (2012-08-01)

Stereotactic ablative radiotherapy as single treatment for early stage non‐small cell lung cancer: A single institution analysis
by: Xiaoli Zheng, et al.
Published: (2021-03-01)

Thermal Ablation versus Stereotactic Ablative Body Radiotherapy to Treat Unresectable Colorectal Liver Metastases: A Comparative Analysis from the Prospective Amsterdam CORE Registry
by: Sanne Nieuwenhuizen, et al.
Published: (2021-08-01)

Can reducing planning safety margins broaden the inclusion criteria for lung stereotactic ablative body radiotherapy?
by: Wsam Ghandourh, et al.
Published: (2021-09-01)

Developments in Stereotactic Body Radiotherapy
by: Anoop Haridass
Published: (2018-12-01)

Treatment of Early Stage Non-Small Cell Lung Cancer: Surgery or Stereotactic Ablative Radiotherapy?
by: Esengül Koçak Uzel, et al.
Published: (2015-03-01)

IMMUNE EFFECTS OF STEREOTACTIC ABLATIVE RADIATION THERAPY IN PATIENTS WITH MALIGNANT TUMORS: LITERATURE REVIEW
by: A. Yu. Zozulya, et al.
Published: (2020-10-01)

Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function
by: C. Senger, et al.
Published: (2019-10-01)

Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer
by: Adam Mutsaers, et al.
Published: (2017-06-01)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
by: Eleanor Clarke, et al.
Published: (2020-09-01)

Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases
by: Cyrielle Scouarnec, et al.
Published: (2019-08-01)

Stereotactic body radiation therapy in the treatment of ovarian cancer
by: Roman O. Kowalchuk, et al.
Published: (2020-05-01)

Adrenal metastases: clinical manifestations and surgical outcomes
by: V. R. Latypov, et al.
Published: (2018-07-01)

A decision tool for radiographer-led abdominal image-guided stereotactic ablative body radiotherapy – Experience from a single institution
by: Mairead Daly, et al.
Published: (2021-09-01)

Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
by: Byung Kwan Park, et al.
Published: (2021-06-01)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
by: Rodney E. Wegner, et al.
Published: (2019-05-01)

Stereotactic Ablative Radiosurgery for Locally-Advanced or Recurrent Skull Base Malignancies with Prior External Beam Radiation Therapy
by: Karen Mann Xu, et al.
Published: (2015-03-01)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
by: Laila König, et al.
Published: (2020-02-01)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
by: Charlotte L. Deijen, et al.
Published: (2021-09-01)

Late metastatic presentation is associated with improved survival and delayed wide‐spread progression after ablative stereotactic body radiotherapy for oligometastasis
by: Xuguang Chen, et al.
Published: (2021-09-01)

A Valuable Book Collection of SABRE-Zagreb Donated to the Zagreb Natural Sciences Faculty
by: Valenta, A.
Published: (2010-06-01)

SABR模型與SABR-LMM模型之實證分析
by: 毛迦南, et al.

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care
by: Adam J. N. Raymakers, et al.
Published: (2021-05-01)

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
by: Nicholas Hardcastle, et al.
Published: (2021-08-01)

Clinical efficacy of chemoembolization with simultaneous radiofrequency ablation for treatment of adrenal metastases from hepatocellular carcinoma
by: Hongjun Yuan, et al.
Published: (2018-07-01)

Adrenal Artery Ablation for the Treatment of Hypercortisolism Based on Adrenal Venous Sampling: A Potential Therapeutic Strategy
by: Zhou Q, et al.
Published: (2020-10-01)

The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases
by: Alexander eChi, et al.
Published: (2014-06-01)

A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer
by: Anurag K. Singh, et al.
Published: (2018-11-01)

Percutaneous radiofrequency ablation of adrenal metastases from hepatocellular carcinoma: a single-center experience
by: Jingzhi Huang, et al.
Published: (2019-06-01)

Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity
by: Christy Goldsmith, et al.
Published: (2018-10-01)